21 January 2021
Immunicum AB (publ) Declares Transitions in Board of Directors
Immunicum AB (publ: IMMU.ST) this day launched that Michael Oredsson has made up our minds to resign his location as chairman and member of Immunicum’s Board of Directors, effective as of the Unheard of General Assembly (EGM) that will seemingly be held the following day on January 22, 2021. The Board has agreed to nominate Christine Lind, currently serving as board member, as interim chairman until the following Annual General Assembly (AGM), to be held on Could presumably well moreover 4, 2021.
“I comprise been allotment of Immunicum’s style since 2018 and comprise been very impressed by the clinical progress and achievements over the final years,” commented Michael Oredsson. “For the following stage of Immunicum’s transformation, it’s miles an acceptable time at hand over the chairman role and I’m assured that the Firm can abet from the wealth of abilities that Christine has in guiding strategy and bringing together abilities to manufacture fee in biopharmaceutical companies.”
“On behalf of the entire board, I would love to thank Michael for his tireless make stronger and essential contributions to Immunicum over the final years,” said Christine Lind. “His dedication to making definite that Immunicum’s capabilities proceed to transfer toward commercialization and attain patients has been crucial for the advancement of the corporate. With the mixed strengths following primarily the most contemporary industry aggregate and both ilixadencel and DCP-001 in clinical style, I’m bright about Immunicum’s capacity to bring future therapies to patients. I’m honored to work with my fellow board people and Immunicum’s government crew to manufacture Immunicum’s location as a pacesetter in cell-based fully therapies.”
On the EGM, as previously launched, it’s miles proposed is to elect Dharminder Chahal and Andrea van Elsas, Ph.D., as unusual people of the Board of Directors. If the vote on the EGM is in prefer of these elections, the board will seemingly be peaceable of Christine Lind as interim chairman, and Sven Andreasson, Dharminder Chahal, Charlotte Edenius M.D., Ph.D., Andrea van Elsas Ph.D., Steven Glazer M.D., and Helén Tuvesson Ph.D., as people for the duration until the AGM.
The solutions is such recordsdata that Immunicum is obliged to web public pursuant to EU Market Abuse Legislation. The solutions was once released for public disclosure via the contact americans detailed below on 21 January 2021, at 08: 00 am CET.
For extra recordsdata, please contact:
Michael Oredsson and Christine Lind
Phone: +46 8 732 8400
Electronic mail: email@example.com
About Immunicum AB (publ)
Immunicum is leveraging its unparalleled abilities in dendritic cell biology to manufacture contemporary, off-the-shelf, cell-based fully therapies for web and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical style that are in step with intratumoral priming and cancer relapse vaccination, the corporate targets to make stronger survival outcomes and quality of lifestyles for a huge population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com